18+ ONLY · LAB RESEARCH ONLY · NOT FOR HUMANS OR ANIMALS

← BSR Intelligence

Pharma & GLP-1 · 17 Nov 2026

Pfizer Secures $1.5 Billion from Blackstone to Advance Once-Monthly GLP-1 Berobenatide: What the Deal Signals for the Extended-Dosing Peptide Race

Pfizer and Blackstone Life Sciences have signed a co-funding agreement under which Blackstone will cover up to $1.5 billion of berobenatide's development costs through 2028. The deal underscores the growing commercial and investor conviction behind extended-dosing GLP-1 peptides, with a separate AI-guided oral cyclic peptide collaboration between Hansoh Pharma and AilsynBio announced days later.

12 sources cited

Key takeaways

  • Pfizer and Blackstone Life Sciences announced a co-funding agreement on 11 November 2026, under which Blackstone will provide up to $1.5 billion of berobenatide's development costs through 2028, while Pfizer retains full operational control.
  • Berobenatide is an investigational, once-monthly GLP-1 receptor agonist peptide now in Phase 3; if approved, it would be the first monthly injectable GLP-1 receptor agonist on the market.
  • The deal arrives days after Hansoh Pharma signed a separate AI-guided oral cyclic peptide collaboration with AilsynBio, reinforcing a pattern in which both extended-dosing injectable and oral peptide formats are attracting structured capital.
  • Neither compound is approved in any jurisdiction; both remain strictly investigational.

The Pfizer–Blackstone deal: structure and terms

Pfizer and Blackstone Life Sciences announced the agreement on 11 November 2026. Under its terms, funds managed by Blackstone — drawing on both its Life Sciences vehicle and its perpetual private equity strategy BXPE — will pay up to $1.5 billion of berobenatide's clinical development costs through 2028. Blackstone does not acquire any rights or ownership in berobenatide, and Pfizer retains full operational control and all decision-making authority over the programme.

In return, Blackstone becomes eligible for milestone-based payments tied to two conditions: US regulatory approval of monthly injectable berobenatide as a monotherapy for chronic weight management, and the achievement of specified commercial sales milestones. The arrangement is therefore structured as a development cost-share with performance-contingent upside for the funder rather than an equity or licensing transaction.

Blackstone Life Sciences currently has $18 billion in assets under management, and the firm closed a record $6.3 billion BXLS VI fund — described as the largest private life sciences financing ever raised — before committing to this arrangement. The berobenatide deal continues an existing relationship between the two organisations.

What is berobenatide?

Berobenatide is a synthetic peptide GLP-1 receptor agonist classified as an investigational compound, with Phase 3 as its global highest development status. Pfizer acquired it through its approximately $10 billion takeover of Metsera, completed in late 2025. The compound was previously known as MET-097i in the Metsera era and is also referenced as PF-08653944 and PF'3944 in trial registrations.

The molecule's key pharmacological property is an extended plasma half-life, achieved through a lipidation strategy that enables the drug to bind the GLP-1 receptor with or without full dissociation from albumin. This gives berobenatide an extended half-life that enables potential for monthly dosing. The compound is also characterised as a fully biased GLP-1 agonist: it activates cyclic adenosine monophosphate signalling preferentially over beta arrestin, which inhibits receptor internalisation and may support prolonged receptor availability, though the clinical significance of this biased agonism profile has not yet been confirmed in head-to-head outcomes data.

The dosing scheme tested in Phase 2b used a 12-week weekly titration phase, followed by a switch to once-monthly maintenance injections. In the VESPER-3 trial, weight loss continued after the transition from weekly to monthly dosing, with Phase 2b studies reporting non-placebo-adjusted weight loss of 15.9%. If Phase 3 data are positive and regulatory approval is obtained, berobenatide would be the first GLP-1 receptor agonist dosed just once a month — a fourfold reduction in injection frequency compared with semaglutide and tirzepatide.

Phase 3 programme scope

Pfizer has described 10 ongoing or planned Phase 3 trials covering weight management and conditions linked to obesity, including obstructive sleep apnea and knee osteoarthritis. The pivotal Phase 3 study for monthly maintenance dosing — VESPER-6 — is currently open for enrolment. Pfizer is also exploring berobenatide in combination with other nutrient-stimulated hormone peptides, including amylin analogues, through a companion study called SOLIS-1 which is investigating an ultra-long-acting amylin analog (PF'3945) as a monotherapy and in combination with berobenatide. The safety profile observed in Phase 2b was consistent with the GLP-1 receptor agonist class, with a mild, transient increase in nausea upon switching to monthly dosing that improved with continued treatment.

Competitive context

The Blackstone funding announcement came weeks after orforglipron (Foundayo) received regulatory approval in China, and during ObesityWeek 2026, where lower-dose CagriSema data were reported. The GLP-1 drug class is operating at scale: tirzepatide is projected to generate more than $45 billion in global sales in 2026, with semaglutide forecast at $39.5 billion. That commercial backdrop makes the Blackstone co-funding structure intelligible: the investor is effectively wagering that monthly dosing — rather than efficacy supremacy — can carve out a commercially distinct position for berobenatide.

Pfizer's strategy, as outlined in publicly available trial documentation, appears to target adherence and accessibility rather than raw weight-loss percentage, given that Phase 2b efficacy data trail tirzepatide figures. Whether that positioning is sufficient to attract prescribers in a market led by established weekly injectables and, increasingly, oral formulations remains an open research and commercial question that the Phase 3 programme is designed to answer.

Oral cyclic peptides: Hansoh–AilsynBio deal

One day before publication of this article, a separate but thematically connected deal was disclosed. China's Hansoh Pharma signed a drug discovery collaboration with Hong Kong-based AilsynBio to develop oral cyclic peptide therapeutics using artificial intelligence, in an agreement worth up to RMB 317 million (approximately USD 45 million) plus royalties, confirmed in Hansoh's HKEX filing dated 13 November 2026.

Under the agreement, Hansoh will license AilsynBio's AI discovery platform, select therapeutic targets, and retain the right to acquire intellectual property in resulting programmes. AilsynBio describes the platform as a closed-loop system combining proprietary AI with experimental validation, integrating generative AI and quantum chemistry approaches with a proprietary database of hundreds of millions of data points. The collaboration targets oral cyclic peptide drug candidates, a modality in which poor oral bioavailability remains a significant technical challenge.

Hansoh has existing experience in oral peptide development: its oral IL-23 receptor antagonist AVR-001 (a cyclic peptide) was licensed to Avere Therapeutics for development outside Greater China earlier in 2026. The AilsynBio collaboration adds an earlier-stage, AI-guided discovery capability to that existing oral peptide activity.

Implications for research and procurement

For UK research laboratories procuring peptide reference standards and research-grade materials, two practical observations follow from these commercial developments.

First, berobenatide is a synthetic peptide with a specialised lipidation chemistry. As a fully biased GLP-1 receptor agonist built on an exendin-4-derived backbone, it is structurally distinct from semaglutide (a human GLP-1 analogue) and tirzepatide (a GIP/GLP-1 dual agonist). Research groups working on extended-half-life GLP-1 mechanisms, biased agonism, or albumin-binding lipidation strategies should note that the compound remains investigational and is not approved in any jurisdiction, including the UK. The MHRA has issued no guidance specific to berobenatide to date.

Second, the Hansoh–AilsynBio deal is symptomatic of an accelerating interest in AI-guided cyclic peptide design. Cyclic peptides present inherent oral bioavailability challenges that computational approaches are being applied to address. Procurement teams supporting academic research into cyclic peptide chemistry should be aware that the analytical characterisation demands for these molecules — particularly conformation-dependent HPLC and mass spectrometry confirmation — differ meaningfully from linear peptide standards.

Neither berobenatide nor any AilsynBio-derived compound is currently available as a research-grade or reference standard material from regulated suppliers in the UK.


All compounds discussed are investigational. BSR Intelligence does not provide clinical, investment, or regulatory advice. Procurement decisions should be made in accordance with MHRA guidelines and institutional ethics frameworks.

COMPOUNDS IN THIS BRIEFING

Research-grade material, HPLC verified, certificate of analysis with every order.

THE WEEKLY BRIEFING

The week's Intelligence in one email, every Friday morning.

Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.

Published by BSR — Biotech Scientific Research. For research and laboratory use only · not for human consumption.

More in Pharma & GLP-1